|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
So, we attempted to evaluate the association between dopamine D2 (DRD2) receptor, serotonergic (5HT2A) receptor and CYP2D6 gene polymorphisms and response to treatment with risperidone in persons with schizophrenia from North India.
|
28692863 |
2017 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
|
10096261 |
1999 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data suggest that the CYP2D6 gene may not be a susceptibility gene for schizophrenia in Chinese schizophrenic patients.
|
11702057 |
2001 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
LHGDN |
The present study shows a lower frequency of PMs in schizophrenic patients than in healthy volunteers supporting the hypothesis of a potential role of CYP2D6 in the vulnerability to schizophrenia.
|
17325735 |
2007 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For example, an elegant roadmap was laid out a year ago by Karolina Kauppi and colleagues wherein they combined a data set for schizophrenia risk genes and another set of genes associated with antipsychotic drug targets.<sup>3</sup> Using this "network biology" approach, they identified four schizophrenia risk genes that were also antipsychotic drug targets (GRM3, DRD2, CHRM4, and CYP2D6); they also found several molecular targets that are not currently connected to antipsychotic drug treatment, providing researchers with some potential targets for novel therapeutics.<sup>4</sup>.
|
31340894 |
2019 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.
|
9713905 |
1998 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We tested whether substance abuse disorder and suicidal behavior were associated with the CYP2D6 and CYP2C19 genotypes among patients with schizophrenia.
|
18520596 |
2008 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 poor metabolizer genotype seems not to be a determining factor of schizophrenia susceptibility in Brazilians.
|
19761369 |
2009 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the relationship between several functional polymorphisms in genes coding for dopamine metabolism and transport enzymes (MAO-A VNTR; MAO-A 941T>G; DAT VNTR; DAT -67A/T; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6) and the frequency of schizophrenia.
|
20041956 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
There actually exists significant implication of CYP2D6 genetic polymorphisms on the metabolic kinetics of risperidone, little is known about the extent of CYP2D6 impacting human D2 and 5-HT2A receptor occupancies as well as the clinical efficacy and efficacy in schizophrenia treatment.
|
30281999 |
2018 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Common CYP2D6 mutant alleles were not associated with schizophrenia or with disease symptoms, antipsychotic-related adverse effects, or attitudes toward treatment.
|
10610012 |
1999 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
|
17715206 |
2007 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
|
23066770 |
2012 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
|
12616663 |
2003 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Reported herein are two NMS patients with schizophrenia who were found to possess a CYP2D6 gene deletion allele (CYP2D6*5).
|
16048458 |
2005 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
We investigated the relationship between several functional polymorphisms in genes coding for dopamine metabolism and transport enzymes (MAO-A VNTR; MAO-A 941T>G; DAT VNTR; DAT -67A/T; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6) and the frequency of schizophrenia.
|
20041956 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
The authors studied the correlations between the steady-state plasma concentrations (Css) of aripiprazole and its active metabolite, dehydroaripiprazole, and those of haloperidol in 19 Japanese patients with schizophrenia, together with the effects of CYP2D6 genotypes on the steady-state kinetics of these compounds.
|
24739668 |
2014 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.
|
7712118 |
1994 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders.
|
21142916 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of this study imply the potential role of CYP2D6 genotyping in personalizing risperidone therapy in patients with schizophrenia to reduce the incidence of adverse extrapyramidal symptoms.
|
20599499 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
|
21157400 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified 18 PM patients with a schizophrenia spectrum diagnosis from a clinical database covering all patients who have been analyzed in an ongoing standardized CYP2D6 screening program.
|
19521114 |
2009 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the CYP1A2 and CYP2D6 polymorphisms are not likely to play a major role in the development of polydipsia in schizophrenia, although further studies testing other alleles of CYP1A2 and CYP2D6 using different ethnic populations are warranted.
|
16775389 |
2006 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 loss of function alleles may predispose to tardive dyskinesia in patients with schizophrenia under treatment, but bias cannot be excluded.
|
15861039 |
2005 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6.
|
12432967 |
2002 |